Calamos Advisors
LLY icon

Calamos Advisors’s Eli Lilly LLY Stock Holding History

Calamos Advisors’s Portfolio LLY Stock Details LLY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-23,100
Closed -$8.45M – 1179
2022
Q4 		$8.45M Sell
23,100
-3,000
-11% -$1.06M 0.04% 526
2022
Q3 		$8.44M Hold
26,100
– – 0.04% 536
2022
Q2 		$8.46M Buy
+26,100
New +$7.83M 0.04% 551

Other funds holding LLY

Lilly Endowment
Lilly Endowment Indiananapolis, Indiana $108B AUM 53.87% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Calamos Advisors's LLY Position: Q2 2026 in Review

Calamos Advisors reduced its Eli Lilly (LLY) stake by 8.3% in Q2 2026, selling an estimated $26.1M and leaving 283,001 shares worth $339M. The position accounts for 1.13% of the portfolio, ranked #13.

Calamos Advisors first reported a position in LLY in Q2 2013 and has held it in 53 quarters since. 4,624 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Calamos Advisors held 283,001 shares of Eli Lilly worth $339M as of Q2 2026.
  • Calamos Advisors sold 25,496 Eli Lilly shares in Q2 2026, an estimated $26.1M.
  • Eli Lilly made up 1.13% of Calamos Advisors's portfolio in Q2 2026, its #13 holding.
  • Calamos Advisors first reported a position in Eli Lilly in Q2 2013 and has held it in 53 quarters since.
  • 4,624 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Calamos Advisors's 13F filing for Q2 2026, filed 31 Jul 2026.